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ABSTRACT
Electronic cigarettes, or e-cigarettes, have been scrutinized by the Food and
Drug Administration and other public health organizations for issues related to
quality control and efficacy. Erratic nicotine delivery and numerous toxic compounds
in refill solutions have been reported. The ultimate goal of this research is to add to
the growing amount of knowledge regarding e-cigarette ingredient content, safety,
and quality. Standards of the tobacco alkaloids nicotine, anabasine, cotinine, and
myosmine were prepared and quantified using high performance liquid
chromatography (HPLC). Various elution schemes were tested and adjusted for
optimal analyte resolution, and a final elution scheme was developed to characterize
e-cigarette alkaloids.
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INTRODUCTION
Purpose
Due to the small number of studies regarding the safety and efficacy of
electronic cigarettes, full ingredient content and concentrations remain uncertain in
many varieties of electronic cigarette refill solutions. These products have only
existed for sale in the U.S. for a relatively short time; very little comprehensive
research has been conducted regarding their long-term health effects or associated
risks. Further investigation is needed to address possible inconsistencies in the
labeling of e-cigarette refill solutions. The objectives for this project are:
•

to study the alkaloids found in electronic cigarettes,

•

to study mobile phase theory as it pertains to the elution of nicotine and
related alkaloids using high performance liquid chromatography (HPLC), and

•

to develop an elution scheme capable of quantifying the alkaloids nicotine,
anabasine, cotinine, and myosmine found in electronic cigarette filling
solutions with HPLC.

What’s an E-Cigarette?
Electronic cigarettes, also known as electronic nicotine delivery systems
(ENDS), e-cigarettes, or e-cigs, are devices designed to deliver nicotine in a manner
that mimics traditional tobacco smoking. Most e-cigarettes consist of a mouthpiece, a
cartridge containing nicotine in solution, a heating element, an airflow sensor, a
rechargeable lithium ion battery, and an LED. Upon inhalation, the sensor is triggered
by negative pressure, activating the heating element which vaporizes the liquid
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contained in the cartridge and heats air as it is inhaled. The LED located at the tip also
lights up to imitate the burning of a traditional cigarette. The resulting aerosol made
from the vaporized liquid and water vapor from the air creates an observable fog that
is released upon exhalation.1 Designs may vary according to brand; some e-cigarettes
contained a fused cartridge and heating element called a “cartomizer” that is meant to
be disposable. A diagram showing the inner components of a typical electronic
cigarette is given in Figure 1.

Figure 1: Electronic Cigarette Diagram. 1 = light-emitting diode (LED); 2 = lithium
ion rechargeable battery; 3 = airflow sensor; 4 = heating element; 5 = filling solution
cartridge; 6 = mouthpiece.
E-Cigarettes Vs. Traditional Cigarettes
While e-cigarettes superficially resemble traditional tobacco cigarettes, they
are more closely related in internal design and operation to drug delivery systems
such as inhalers and nebulizers.1 The method of release for conventional cigarettes
versus e-cigarettes is quite different: unlike conventional cigarettes, which release
compounds in the form of smoke from combustion of tobacco, e-cigarettes release
compounds in vapor form due to evaporation; for this reason, the term ‘vaping’ has
been made analogous to smoking by e-cigarette industries and users alike.2
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Once used, empty e-cigarette cartridges may either be disposed or refilled
with liquid purchased from the manufacturer. These liquids contain nicotine marketed
in a variety of concentrations, as well as food-grade flavorings and a humectant
(typically propylene glycol and/or vegetable glycerin) with some variability
depending on manufacturer and flavor of liquid purchased. Other ingredients may
include ethanol along with other complex alcohols, diols, nicotine-related alkaloids
and colorings.3 Ethanol is often present as a flavoring component, or may be related
to nicotine extraction from tobacco leaves.4 Refill solutions come in a variety of
flavors such as waffles, whiskey, pina colada, blueberry, and popcorn. Flavors other
than tobacco and menthol are banned for conventional cigarettes under the Family
Smoking Prevention and Tobacco Control Act of 2009 to prevent targeting tobacco
products to youth; this ruling does not apply to any other tobacco products.5 Other
detected ingredients have included herbal preparations designed to have a therapeutic
effect, or medications such as rimonabant and amino-tadalafil.6 Some e-cigarette
consumers even choose to prepare their own refill solutions by extracting nicotine
from used tobacco cigarettes; a variety of homemade formulations containing
ingredients similar to those listed above may be found online through electronic
cigarette forums.
Production & Sales of E-Cigarettes
E-cigarette technology was first patented in 2003 by Hon Lik, a Chinese
pharmacist who developed the atomization device that vaporizes nicotine in
electronic cigarettes, cigars, and pipes.7-8 The products were first marketed in China
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by the company Ruyan (meaning ‘like smoke’) in 2004. 7,9-10 Ruyan received an
international patent in 20077, and the e-cigarette has since been marketed worldwide
in countries such as Brazil, Canada, Finland, Israel, Lebanon, the Netherlands,
Sweden, Turkey, the United Kingdom, and the United States.8,11
Though mechanical electronic cigarette components such as the sensor,
heating element, and cartridge are manufactured predominantly in China7, refill fluids
are produced domestically. One popular manufacturer produces refill liquids in
Wisconsin for Blu, a company which maintains a significant portion of the American
e-cigarette market.12 Nicotine strength of refill solutions and cartridges vary from
brand to brand in terms of reported equivalency to traditional cigarettes. Veppo states
that one 10 mL bottle of refill fluid used over time is roughly equal to smoking ten
packs of cigarettes13. In contrast, Vapor4Life equates 30 mL of its refill fluid to 25-30
replacement cartridges, each of which corresponds to approximately three-fourths to
one whole pack of cigarettes. A single 30 mL bottle from Vapor4Life would therefore
be comparable to smoking roughly 24 packs of cigarettes.14
E-cigarettes represent a rapidly growing industry. The market has doubled in
size every year since 2008, and was projected to reach one billion dollars in sales in
2013.15 The majority of electronic cigarette sales are from online, with a portion of
sales attributed to mall kiosks and convenience stores where they may be sold without
a tobacco license in certain parts of the U.S.7, 16-17 In a study designed to collect
information regarding e-cigarette product preferences and opinions, those who
responded to surveys online were more likely to be aware of electronic cigarettes.17
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Internet sales of electronic cigarettes have generated concern regarding their
availability to minors who could not otherwise purchase tobacco or other nicotine
delivery products. One study found that awareness of electronic cigarettes was
inversely related to age, suggesting that young adults in the age range of 18-29 are
most likely to try e-cigarettes.18 Similarly, the awareness of e-cigarettes has been
found highest among white, high-income, educated males from the ages of 18-24 who
were self-reported nondaily smokers.17 A study which compared the volume of
internet searches for terms related to e-cigarettes with those of approved nicotine
replacement methods found that e-cigarette searches first exceeded those of FDAapproved nicotine replacement therapy in 2008, and has since continued to rapidly
outpace other forms of nicotine replacement.19
Advertising campaigns for electronic cigarettes resemble those of traditional
cigarettes before they were banned in the U.S.—physically attractive men and women
are shown vaping, with slogans such as “Cigarettes, You’ve Met Your Match” and
“Rise from the Ashes”.20-21 Celebrity endorsements are also becoming increasingly
prominent.7 Commercials have aired on popular cable stations in the U.S., though
broadcast channels have refrained from airing e-cigarette ads.21
The cost of e-cigarettes has decreased dramatically in conjunction with their
rising popularity in the U.S.—companies which once sold units for as much as $200
in 2009 were as little as $21 as of 2012.22 The devices are often advertised as costeffective alternatives to traditional cigarettes. One survey found that users spent $33
per month for e-cigarette supplies as compared to an average of $150 to $200 per

11

month to smoke one pack of traditional cigarettes per day. The study suggests that
cost is a major contributing factor to the popularity of the e-cigarette.23
Public Opinion & Regulation
A multitude of surveys have been performed and published regarding the
general opinions of e-cigarette users with regards to perceived health benefits,
awareness, satisfaction, and user demographics.16-19, 23-31 Popular cited reasons for
using e-cigarettes include a desire to quit smoking, reduced cost, the perceived ability
to vape in places where smoking is normally prohibited, to avoid disturbing others
while smoking, and a perceived reduction in health risks when compared to
traditional cigarettes.16 A majority of e-cigarette users reported in one survey that the
product helped them quit or cut down on smoking and that e-cigarettes “feel healthier
than smoking”. Only about a third of respondents had tried to reduce e-cigarette
consumption, however, and a majority of those who made attempts were self-reported
as “not very successful”.24 These results suggest that while e-cigarettes may have the
potential to reduce cigarette use among current smokers, they may not be effective at
reducing nicotine dependence and carry a risk for abuse.
Despite their ubiquity in the U.S. market, formal regulatory classification for
the e-cigarette is still under consideration. In 2008, the World Health Organization
issued a warning to e-cigarette manufacturers stating that e-cigarettes should not be
marketed as a smoking cessation tool. “WHO knows of no evidentiary basis for the
marketers' claim that the electronic cigarette helps people quit smoking. Indeed, as far
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as WHO is aware, no rigorous, peer-reviewed studies have been conducted showing
that the electronic cigarette is a safe and effective nicotine replacement therapy”.11
The American e-cigarette regulation dispute began when the U.S. Food and
Drug Administration first attempted to halt Smoking Everywhere e-cigarette imports
from China in 2008 on the grounds that the products were unapproved drug delivery
systems under Federal Food, Drug, and Cosmetic Act. A U.S. District Court in
Washington D.C. overruled the FDA’s attempt to regulate e-cigarettes as drug
delivery devices in 2010 and instead suggested that they fall under the regulatory
description of tobacco products, defined as “any product made or derived from
tobacco that is intended for human consumption”.32-35 This ruling directed the FDA to
regulate e-cigarettes under the Family Smoking Prevention and Tobacco Control Act
signed under the Obama administration in 2009. FDA representatives have stated that
they would prefer regulating the products as drug delivery devices as it would offer
greater control, allowing the administration to fully evaluate each electronic cigarette
and refill solution for consumer safety and efficacy prior to sale.33 While this recent
ruling does not grant the FDA the power to block e-cigarette imports, it does grant the
administration some control over marketing and quality control practices. Available
options for the FDA to regulate e-cigarettes include removal from the consumer
market for a premarket review, higher taxation, limitation of different flavors in
tobacco products other than cigarettes, the introduction and/or expansion of warning
labels, and restriction of manufacturer health claims.5
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Other countries are currently evaluating similar approaches to the regulation
of electronic cigarettes. The United Kingdom’s Medicines and Healthcare Products
Regulatory Agency cited an FDA study which found carcinogenic nitrosamines and
diethylene glycol in refill solutions in its decision to try regulating e-cigarettes as
medical products. This form of regulation would result in a similar testing and
approval process prior to allowing the sale of different electronic cigarettes in the
U.K.36
E-Cigarette Alkaloids: General Properties
Existing patents for e-cigarette refill formulations and the presence of
tobacco-specific impurities suggest that the nicotine added to some refill solutions is
not chemically pure but is rather an extract from tobacco. An alkaloid is generally
defined as a naturally occurring, basic, nitrogen-containing compound that exhibits a
pharmacological effect. Alkaloids can be found in food such as potatoes, tomatoes,
coffee, tea, cocoa, and pepper.37 Common tobacco alkaloids include: nicotine,
cotinine, nicotine-1’-N-oxide, nornicotine, nicotyrine, nornicotyrine, myosmine, 2’,3bipyridyl, anabasine, and anatabine; over 20 pyridyl-type alkaloids have been found
in tobacco.37-38 Minor tobacco alkaloids have been found to amplify the physiological
effects of nicotine.39 Nicotine, anabasine, cotinine, and myosmine were chosen for
this study both for their cost and in response to preexisting research conducted by the
FDA which detected the presence of these alkaloids in e-cigarette refill solutions.6
The tobacco alkaloids are all structurally based around pyridine and are substituted at
the 3-position with an alicyclic base; nicotine, cotinine, and myosmine all contain a
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modified pyrrolidine ring, whereas anabasine contains a piperidine ring. Most are
weakly basic and thus have the capacity to ionize in an acidic solvent. The structures
of tobacco alkaloids of interest and estimated pKa values are listed in Figure 2.
Tobacco alkaloids affect the body by binding to nicotinic acetylcholine receptors at
the protonated alicyclic base; compounds such as cotinine whose pKa values are
below physiological pH are regarded as inactive under these conditions.38
Nicotine
Nicotine is the primary alkaloid found in tobacco (Nicotiana tobacum). While
it is generally known as the addictive agent found in recreational tobacco products, it
has been studied for its potential to treat Alzheimer’s disease, Parkinson’s disease,
and ulcerative colitis.40 (S)-(-)-nicotine predominates in its natural state and possesses
biological activity, though the enantiomer (R)-(+)-nicotine may form due to added
heat while smoking.38, 40 Nicotine is regarded as one of the most heavily abused
substances of all time—smoking is the top preventable cause of death in the world,
and is estimated to cause one in every five U.S. deaths through both direct and
indirect smoke exposure.41-42 It behaves as a stimulant in the body, acting on nicotinic
acetylcholine receptors in the brain and triggering the release of dopamine along with
a variety of other neurotransmitters.40 Nicotine increases the heart rate, metabolism,
and memory, as well as suppressing appetite.38, 43-44 Although nicotine is very toxic,
nicotine poisoning from cigarettes is rare, and occurs most often from cutaneous
exposure or ingestion of tobacco leaves or pesticides. The estimated lethal adult oral
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dose of nicotine is between 40 and 60 mg, or approximately 0.6 to 0.9 mg/kg; the
average tobacco cigarette contains 0.8 to 1.1 mg of nicotine.38, 45

Figure 2: Structures of the Tobacco Alkaloids Nicotine, Anabasine, Cotinine, and
Myosmine With Predicted pKa Values46
Anabasine
Anabasine is perhaps best known for its historical use as an insecticide.47 It is
thought that nicotine alkaloids are produced by the tobacco plant as a natural insect
repellant.48 Anabasine may also be detected in cigarette smoke and body fluids of
smokers. Due to its structural similarity, anabasine is thought to react similarly to
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nicotine in the body. The median lethal dose for anabasine in mice is estimated
between 11 and 16 mg/kg.47 Anabasine and similar alkaloids containing piperidine
are known to be teratogenic to livestock, resulting in defects such as cleft palate and
multiple congenital contractures.49
Cotinine
Between 70 and 80% of nicotine in the body is oxidized in the liver with the
addition of a carbonyl group on the pyrrolidine ring to form cotinine, a major tobacco
alkaloid and nicotine metabolite, before undergoing further oxidation to other
compounds.50-51 The long half-life of cotinine (16 to 20 hours) compared to that of
nicotine (1 to 4 hours) makes cotinine a good candidate for detection in analytical
studies to determine a subject’s nicotine intake.52 Cotinine is suspected to have its
own reactive mechanism distinct from nicotine in the body, though it has been shown
to cause behavioral responses similar to that of nicotine.53-54 It is less toxic than
nicotine, and does not produce withdrawal symptoms.
Myosmine
Myosmine is found in very small quantities in tobacco; amounts found in
cigarette smoke are 50 to 100 times less than nicotine.55 It is genotoxic and has the
potential to form carcinogenic intermediates such as N’-nitrosonornicotine in the
body. Interestingly, myosmine has been detected not only in tobacco, but also in a
variety of foods such as cereals, nuts, and milk.56 Myosmine has been detected in
non-smokers’ plasma and saliva at levels as much as 5 ng/mL; these results indicate
that myosmine is entering the body through additional routes besides passive
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smoking.55 The cutoff alkaloid concentration used to determine if a subject has been
smoking is above 5 ng/mL. Tests measuring nicotine intake therefore remain valid
even if myosmine is present in the body from sources unrelated to smoking.57
Existing E-Cigarette Research
Common e-cigarette refill solution ingredients and exhalation byproducts have
been identified and quantified by both high performance and ultra-performance liquid
chromatography, gas chromatography, and NMR spectroscopy.2-3, 6, 58-62
Concentrations of ingredients vary widely according to the manufacturer of the refill
solutions; for example, humectants may be found in a mixture or one may be omitted
in favor of another, i.e. vegetable glycerin instead of propylene glycol or vice versa.
Water content has also been found to vary from less than 1% to as much as 20%.62
Pre-existing research has indicated a need for further studies regarding the
safety and efficacy of e-cigarettes. Quality control studies have found inconsistent or
unclear labeling of nicotine and full ingredient content in refill solutions; nicotine
content is often simply listed in milligrams, with no indication of whether this volume
is per container or per milliliter.9 As stated previously, the median lethal dose of
nicotine is 40 to 60 mg.38, 45 Several of the products among the samples tested claim
to contain well above the lethal dose of nicotine in a single bottle; a 15-mL bottle
with a reported strength of 36 mg/mL, for example, would contain as much as 540 mg
of nicotine. A study which measured aerosol generation from e-cigarettes found that
nicotine delivery and vapor production is often erratic between brands of the same
strength and even from puff to puff of the same e-cigarette.63 Studies measuring

18

carbon monoxide exhalation, heart rate, and/or nicotine levels in the blood plasma of
e-cigarette users all demonstrate that nicotine delivery and absorption is less than that
of conventional cigarettes, suggesting that e-cigarettes may be inefficient nicotine
delivery devices.64-65 Other research indicated that nicotine is present in e-cigarette
vapor, presenting a secondhand risk of absorbing alkaloids that is currently not
addressed by e-cigarette manufacturers.2 Nicotine related impurities have been found
in refill solutions, including the toxin diethylene glycol, as well as carcinogenic
nitrosamines that are formed from tobacco alkaloids.60, 66 Furthermore, ‘vaping’ an ecigarette has adverse short-term effects on the pulmonary system.67 E-cigarette vapor
is also reported to contain volatile organic compounds present in tobacco smoke;
other vapor constituents include flavorings and glycerin.2 Finally, since e-cigarettes
have existed in the U.S. for less than 10 years, there have been no studies assessing
the long-term health risks or effects associated with electronic cigarette use or direct
exposure to refill solutions. The ultimate goal of this e-cigarette research is to add to
the growing amount of knowledge regarding content and quality of filling solutions.
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CHROMATOGRAPHIC THEORY
Liquid Chromatography
Liquid chromatography is a type of chemical separation that occurs between a
liquid mobile phase (known as the eluent) and a solid stationary phase, or adsorbent,
contained in a column. The sample containing the compound(s) of interest mixed
with impurities, solvent(s), and/or unknown compounds is placed on the column via
an injection port. While passing through the column, compounds in the sample
separate from each other due to their chemical properties such as molecular weight,
polarity, and pKa. The sample then passes through a detector that displays each
detectable compound in the sample as peaks on a chromatogram. Peaks may be
interpreted by their retention times and area—each compound possesses a unique
retention time, and peak area is related to the amount of each compound. A diagram
depicting a typical HPLC apparatus is given in Figure 3.
High performance liquid chromatography, or HPLC, is a common separation
method used in analytical chemistry. It is often chosen for its sensitivity, adaptability
to both identification and quantification, and for its ability to separate a variety of
organic, inorganic, and organometallic compounds.68 It is able to detect micrograms
of a sample without the decomposition of analytes that is encountered in gas
chromatography.69 HPLC uses pressures of up to 6000 psi mediated by a
reciprocating pump to push liquids through the column; the pressure is often
maintained using a pulse dampener, which allows for reproducibility and fine control
of the eluent flow rate, typically between 0.1 and 10 mL/min.68 Samples ranging
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between less than 1µL and 500 µL in volume are introduced to the column at high
pressures using a sampling loop. Columns contain a tightly packed adsorbent
designed to slow down the sample in the mobile phase for separation. Common
column packing materials range from 3 to 10 micrometers in diameter. In reversed
phase liquid chromatography (RP-HPLC), a polar solvent such as water or
acetonitrile is pushed through a nonpolar column material such as organicallymodified silica. Reversed-phase chromatography is vastly preferred over other forms
of HPLC: almost 90% of all liquid chromatographic analyses feature RP-HPLC. The
main reasons in favor of RP-HPLC are the ability to distinguish between very closely
related compounds and the extent to which the mobile phase may be manipulated to
optimize the elution profile.70 RP-HPLC was therefore chosen as the instrumental
method for this study.
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Figure 3: Block Diagram of HPLC Instrument Components
Compound Identification & Detectors
Identification of compounds in a sample may be achieved through a
combination of their retention times and detector output. The UV absorbance and
retention of the compounds were used for identification in this experiment. The
retention time is defined as the time measured from the initial injection of sample to
the peak absorption time. The void time, or TM, is the time required for unretained
compounds to pass through the column and reach the detector following injection.
Retention times should be adjusted such that analytes do not co-elute with the small
peak corresponding to TM. A Thermo Finnigan chromatograph was used for
preliminary analysis and featured a UV detector with a deuterium lamp wherein the
displayed amount of absorbed ultraviolet light is related to the amount of compound
passing through the detector. The wavelength of maximum absorbance, or λmax, is
unique to the compound being studied. The λmax may be estimated by identifying
different functional groups known as chromophores in the compound that absorb
ultraviolet light. Depending on the detector model, the wavelength of detection may
be adjusted on the HPLC according to the λmax of the organic compound of interest.
Diode array detectors such as the one found in the Agilent 1220 chromatograph are
capable of simultaneous detection at multiple wavelengths, allowing the experimenter
to study mixed samples containing compounds with different λmax values. The λmax is
generally chosen as the wavelength of detection for a compound because it yields the
strongest signal, resulting in improved peak shape and a higher signal-to-noise ratio.68
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The General Elution Problem
Due to the different chemical properties of compounds found in a mixed
sample, achieving good resolution in conjunction with a reasonable retention time
often proves to be difficult. A single set of conditions is rarely ideal for all
components that one may find in a sample. This is commonly known as the general
elution problem, and knowledge of the factors influencing separation is required to
overcome this issue. Often, gradient elution schemes in which the proportions of
solvents are changed with respect to time are used so that the appropriate conditions
may be met to elute a particular component at the desired time. This method can be
used to prevent overlapping peaks, broad peaks, and/or long run times.68
Mobile Phase Theory
The liquid mobile phase used in HPLC may be easily manipulated at
relatively low cost through a variety of factors to optimize retention time and
resolution. Mobile phase adjustment is therefore the primary tool for controlling the
elution profile—eluent composition, organic solvent, pH, and the buffer may all be
changed in creating a unique separation mode. The vast majority of mobile phases in
RP-HPLC when added to a column are hydro-organic mixtures, or mixtures of an
organic solvent and water. Mobile phases must be very pure (HPLC grade or filtered)
to prevent the appearance of background signals or deposition of impurities on the
column. Solubility, pH, stability, and polarity should be considered among other
factors when choosing an appropriate mixture for the mobile phase.70
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Choosing the appropriate organic solvent to be mixed with water as well as
adjusting its concentration has a large impact on the mobile phase strength, i.e. the
degree to which the mobile phase causes the sample components to elute. Depending
on the solubility of the analyte in the organic component of the mobile phase,
increasing the organic solvent concentration may greatly improve or reduce the
quality of peaks.70
Methanol and acetonitrile are preferred organic solvents due to their
miscibility in water, availability, and relatively low UV absorption cutoff (less than
205 nm). Of the organic solvents studied, acetonitrile is considered a stronger solvent
than methanol, meaning that a smaller added percentage of acetonitrile would be
needed to influence the retention of a compound than methanol in a hydro-organic
mixture.70
When organic solvents are added to the mobile phase, a shift in pH is often
observed, even in buffered systems. Leveling effects should be considered when
working with very strong acids or bases mixed in water—bases stronger than OH- or
acids stronger than H3O+ will not remain stable in aqueous solutions.71 Shifts in pH
observed with the addition of organic solvents are commonly due to multiple factors
that affect the interpretation of pH. When a nonaqueous solvent is added, the
conventional definition of pH as it relates to hydrogen ion activity α no longer applies
to the solution. Glass electrodes such as the one used in this study are designed to
make measurements relative to a standard, aqueous buffer as shown in Equation 1

   





  

Eq. 1
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where pHst is the pH of the standard buffer solution (this is often set manually while
calibrating the pH electrode), E is the cell voltage of the sample solution, Est is the
cell voltage of the standard buffer solution, F is the Faraday constant, R is the gas
constant, and T is the temperature.72 When the pH is measured using a glass
electrode, the voltages are entered into the above equation to receive a digitally
displayed pH reading. In order for this equation to be accurate and report a pH value
that corresponds to α, the solution must be dilute, aqueous, and in the mid-pH range.
An increase in pH is typically found when adding an organic solvent such as
methanol to an aqueous buffer.73 This was observed in our study when we were
forced to pre-mix solvents due to pump failure. The factors leading to this increase
are expounded below:
•

pH shifts may be caused by a change in the junction potential between the
outer glass electrode and the inner reference electrode in combination pH
probes such as the one used in this study. When an organic solvent is added,
the junction potentials between the reference and the sample are unequal,
leading to errors in pH measurements.

•

A change in the autoprotolysis constant Kw can lead to pH shifts in organic
solvents. In water, this constant is equal to [H+][OH-] ≈ 10-14. In hydroorganic mixtures, however, this is shifted due to the presence of additional
ions—in the case of added methanol, for example, the CH3O- ion is
responsible for additional anions in equilibrium with the hydrogen ion,
leading to an apparent increase in basicity.
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•

The conventional pH scale ranging from 0 to 14 is altered when organic
solvents are added to aqueous solutions. This change is related to the
concentration of organic solvent. In methanol-water mixtures, for example,
the apparent pH shift due to this effect is less than 0.1 pH units when the ratio
of methanol to water is 50/50; however, in 100% methanol, this effect
contributes to greater than 2 units in the overall pH shift of the solution.

•

Finally, the buffer pKa is altered in organic solvents due to different abilities
to dissolve hydrogen ions under these conditions (see Buffers in RP-HPLC).72
These factors have led scientists to adopt a naming convention regarding the

solution in which a pH sensor is calibrated as it compares to the solution in which the
pH is actually measured. The term  is used when the pH sensor is calibrated in
the same hydro-organic mixture as the sample solvent, whereas  refers to the pH
measured when the electrode was calibrated in an aqueous solution and the sample
pH measurement was taken in a hydro-organic mixture.74 In this study, the measured
pH of mixed mobile phases refers to the .
Buffers in RP-HPLC
Even slight changes in the degree to which a compound exists in its ionized
state can lead to profound changes in its selectivity on a chromatography column.75
When compounds in a sample are capable of ionization, it is therefore important to
include a buffer in the mobile phase to prevent erratic results due to pH shifts that
could lead to different ionized species in the column. Due to the nature of the
reversed-phase column, compounds buffered at ionized states tend to elute first in a

26

mixed sample followed by non-ionized components.70 Considerations for buffers in
HPLC studies include the buffer identity, the buffer pH, the buffering capacity, and
the effects of dilution and/or mixing of buffers with other solvents.
The buffer capacity is an important factor to consider when selecting the
appropriate buffer for HPLC analysis. Buffer capacity β is defined as a buffer’s
ability to resist a change in pH when incremental amounts of acid or base are added to
the solution.76 It may be described using Equation 2











Eq. 2

where dCb is the change in concentration of base, dCa is the change in concentration
of acid, and dpH is the shift in pH.77 This equation demonstrates that the value for
buffer capacity remains positive regardless of the respective positive or negative pH
shift experienced when base or acid is added. β is proportional to both the
concentration of the buffer and to its pKa . The buffering capacity is strongest when
the pH of the buffer is equal to the pKa ± 1; specifically, this is obtained at the pH
corresponding to the buffer’s titration midpoint where the concentration of acid is
equal to that of the conjugate base, or vice versa. It is therefore recommended to
select buffers with pKa values close to the target pH. This phenomenon is shown with
Equation 3, known as the Henderson-Hasselbalch equation

     !

"#$ %
"#%

Eq. 3
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where [A-] is the concentration of the conjugate base and [HA] is the concentration of
the acidic species. As the ratio [A-]/[HA] approaches unity, the term is simplified to
zero and the pH is equal to the pKa.78
Deviations from the buffer pKa can have drastic effects on the buffer capacity:
when a buffer’s pH is one unit from the pKa, the buffer capacity is reduced by onethird; however, when the pH is two units from the pKa, the capacity is reduced by a
factor of 25.77 Shifts in buffer pKa can occur for ionic buffer species due to deviations
from pKa value listed in most literature sources. This is because simple pKa
calculations made from the Henderson-Hasselbalch equation do not normally account
for shifts ionic strength due to the addition of H+ or OH- ions. Anionic acids such as
hydrogen phosphate therefore experience an unexpected shift in the optimal buffering
pH as the concentration of buffer is increased.79
Despite this, the addition of a buffer with a pH within two units of the pKa is
often sufficient to separate compounds when using HPLC. This is because analytes
are often present at very low concentrations once they are separated, making even low
buffer capacities adequate for controlling analyte ionization.76
EXPERIMENTAL
Materials
Cotinine lot 10165472 and nicotine lot 10139194 were purchased from Alfa
Aesar. Myosmine lot 072M4114V and anabasine lot MKBN2341V were purchased
from Sigma Aldrich. The HPLC-grade eluents water, acetonitrile, and methanol were
purchased from Fisher. Phosphate buffers were prepared using monobasic sodium
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phosphate monohydrate and dibasic sodium phosphate purchased from J.T. Baker
Chemical Company.
Standard Preparation
Nicotine, anabasine, cotinine, and myosmine were diluted with HPLC-grade
water to concentrations of 1 mg/mL to make stock solutions of each alkaloid. These
stock solutions were further diluted with HPLC-grade water to a range of
concentrations appropriate for the HPLC. These concentrations were selected to fall
within the reported concentration range of e-cigarette filling solutions when diluted
by a factor of 1000. Common e-cigarette filling solutions allegedly range in strength
from 0 to 36 mg/mL; the pure alkaloids were therefore chosen to be diluted to
strengths of 5, 15, 25, and 40 µg/mL. This range allows the presumed concentrations
of the filling solution samples to fall within the calibration curves for the standards.
Once the alkaloids were successfully identified using HPLC, mixed samples
containing all four alkaloids of the same concentration were similarly prepared with
HPLC-grade water in order to develop an elution scheme that would successfully
elute all four compounds.
Instrument Conditions
A Thermo Finnigan SpectraSystem chromatograph was used for preliminary
determination of the elution scheme in this study. This chromatograph features a
deuterium lamp for spectroscopic UV detection and a reversed phase Thermo
Hypersil C-18 column with a manual injection system. The majority of attempted
elution schemes were developed on this instrument.
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An Agilent 1220 Infinity Series chromatograph was purchased during the
course of this research. It includes a diode array detector capable of simultaneous
detection at a variety of wavelengths, and a 15-cm long reversed phase Poroshell 120
C-18 column with attached amides.80 This instrument and column allowed for
improved reproducibility, better detection limits, and included an automated injection
system. For both the Thermo Finnigan and Agilent instruments, injection volumes
were 5 µL and the flow rate was set to 1.0 mL/min. A final successful elution scheme
was developed on this instrument.
In order to ensure the presence and accuracy of the concentrations of prepared
standards, ultraviolet-visible spectrometry (UV-vis) was used for each alkaloid
concentration. A Varian Cary 100 Bio UV-vis spectrophotometer was used to scan
the ultraviolet-visible spectrum for each compound, allowing for the determination of
λmax needed for detection using the chromatograph.
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RESULTS & DISCUSSION
UV-Visible Spectra
Absorption spectra for the alkaloids are given in Figures 4-7. Analysis of the
alkaloids using UV-vis absorption spectrometry found an expected λmax value of 260
nm for nicotine, anabasine, and cotinine.81 The displayed absorption spectra for some
of the compounds indicate a negative absorption value for the lowest tested
concentration (5 µg/mL); this is due to instrument drift.
Interestingly, myosmine had two distinct absorption peaks at both 234 nm and
260 nm. A shift in λmax towards lower wavelengths (the blue end of the spectrum) is
known as a hypsochromic shift.68 The structure of myosmine reveals an additional
double bond in the pyrrolidine ring (see Figure 2)—contrary to the observed results,
the extended conjugation of the pyridine ring found in this molecule would typically
indicate a red, or bathochromic, shift in absorption.82 The unexpected additional peak
at 234 nm is in fact thought to be due to a bathochromic shift in the absorption
spectrum of the pyridine ring that would normally exist below 200 nm.81
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Figure 4: UV-vis Absorption Spectrum of Nicotine
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Figure 5: UV-vis Absorption Spectrum of Anabasine
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Figure 6: UV-vis Absorption Spectrum of Cotinine
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Figure 7: UV-vis Absorption Spectrum of Myosmine. Note the presence of
two absorbance peaks located at 234 nm and 260 nm.

The existence of two absorbance peaks for myosmine proved to be a valuable
tool for identification of this compound when studied as part of a mixed sample for
HPLC. By using the Agilent instrument’s diode array detector, the mixed sample
could be injected once and reported using wavelengths of detection set to both 260
nm and 234 nm. This enabled myosmine to be quickly and easily differentiated from
the other alkaloids present in a sample. This is shown in Figure 12.
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Mobile Phase Development
During the course of this project, the conditions of the HPLC eluent such as
buffer pH, buffer identity, solvent ratio, and solvent identity were adjusted in order to
achieve well-defined peaks and/or good resolution in mixed samples. The various
attempted mobile phases are given in Table 1.
The first attempted elution scheme for this project was taken from an HPLC
analysis of e-cigarette alkaloids funded by the FDA. According to Table 1, eluent A
consisted of 100% acetonitrile and eluent B consisted of 10% acetonitrile in 20 mM
ammonium formate buffered to a pH of 8.7. This elution scheme featured a complex
gradient that consisted of multiple adjustments over an extended period of time: from
0 to 10 minutes, the elution scheme was programmed to transition from 100% eluent
B to 80% eluent B and 20% eluent A; from 10 to 20 minutes, the scheme transitioned
to 10% eluent B and 90% eluent A; from 20 to 21 minutes, the scheme transitioned to
100% B; and from 21 to 30 minutes, the scheme remained constant at 100% B.6
One possible reason for the inability of this elution scheme to resolve the
alkaloids in this study was the rapid transition from 20 to 21 minutes in the relative
amount of eluent B—it is possible that this did not allow enough time for the column
to equilibrate to eluent B before the next sample was introduced to the instrument.
Another reason may be the condition of the Thermo Finnigan instrument at the time
of the study. Variable pressure and issues regarding reproducibility of results were
observed prior to the failure of one of the eluent pumps. This restricted the Thermo
Finnigan instrument to the use of a single eluent.
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Table 1: Attempted Elution Schemes
Eluent(s)
Mobile
Phase
No.

Method
pH of
Buffer

Gradient/
Isocratic

Instrument

8.7

Gradient
(Trehy)

Thermo Finnigan

25/75

NA

Isocratic
(Kubica)

Thermo Finnigan

MeOH 10 mM phosphate 65/35

6.8

4

MeOH 10 mM phosphate 80/20

6.8

Isocratic

Thermo Finnigan

5

MeOH 50 mM phosphate 80/20

7.9

Isocratic

Thermo Finnigan

6

MeOH 50 mM phosphate 65/35

8.2

Isocratic

Thermo Finnigan

NA

Isocratic

Thermo Finnigan

1
2
3

A

B

ACN

10% ACN in
20 mM formate

MeOH

HPLC H2O

none

A/B

NA

Isocratic
Thermo Finnigan
(Tambwekar)

7

ACN

8

ACN 50 mM phosphate 50/50

8.5

Isocratic

Thermo Finnigan

9

ACN 25 mM phosphate 80/20

4.0

Isocratic

Thermo Finnigan

10

ACN 25 mM phosphate 50/50

4.0

Isocratic

Thermo Finnigan

11

ACN 25 mM phosphate 35/65

4.0

Isocratic

Thermo Finnigan

12

ACN 25 mM phosphate 60/40

7.0

Isocratic

Thermo Finnigan

13

ACN

25 mM acetate

50/50

6.0

Isocratic

Thermo Finnigan

14

ACN

25 mM acetate

35/65

6.0

Isocratic

Thermo Finnigan

15

ACN 25 mM phosphate 35/65

7.9

Isocratic

Agilent

16

MeOH 25 mM phosphate 35/65

7.9

Isocratic

Agilent

17

MeOH 25 mM phosphate 20/80

7.9

Isocratic

Agilent

18

MeOH 25 mM phosphate 50/50

7.9

Isocratic

Agilent

19

MeOH 25 mM phosphate 35/65

7.9

Gradient*

Agilent

MeOH = methanol, ACN = acetonitrile. Elution schemes are listed in the order they
were attempted. *Multiple adjustments were made to this gradient scheme.
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As a result, many mixed hydro-organic eluents were prepared when attempting later
elution schemes on this instrument by combining the buffer and the organic eluent
prior to analysis.
With the development of new elution schemes, adjustments to the buffer pH,
hydro-organic solvent ratio, and buffer concentration were made incrementally
according to the observed retention characteristics of the alkaloids tested. The most
successful elution scheme developed for the Thermo Finnigan HPLC is given below
in Figures 8-11. This elution scheme consisted of 35% phosphate buffered at a pH of
6.8 and 65% methanol run isocratically for 6 minutes (see mobile phase number 3 in
Table 1). This result led to the development of a final successful elution scheme with
similar specifications using the Agilent HPLC.
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Figure 8: HPLC Chromatogram of Cotinine Using Thermo Finnigan HPLC.
Retention time = 2.632 min.
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Figure 9: HPLC Chromatogram of Myosmine Using Thermo Finnigan HPLC.
Retention time = 3.327 min.
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Figure 10: HPLC Chromatogram of Nicotine Using Thermo Finnigan HPLC.
Retention time = 4.390 min.
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Figure 11: HPLC Chromatogram of Anabasine Using Thermo Finnigan HPLC.
Retention time = 5.595 min.

Figures 10 and 11 effectively demonstrate some of the difficulties encountered
during this project while working with the alkaloids nicotine and anabasine: these
alkaloids in particular tended to have stronger retention characteristics on the column.
This was evident by the broader peaks as the retention time was increased when using
the Thermo Finnigan instrument. This is possibly due to the molecular structures
and/or pKa values of these molecules. Both molecules have relatively high pKa values
compared to the alkaloids cotinine and myosmine (see Figure 2). An equilibrium
between the ionized and unionized forms of these molecules located at the alicyclic
base (that is, the nitrogen located in the non-aromatic ring) may exist at the specified
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buffer pH, leading to broadened peaks. In addition, nicotine and anabasine yielded
unusually low signals with peak heights of less than 2 mAU—this result indicates a
low signal-to-noise ratio for these compounds.
In contrast, cotinine and myosmine demonstrate desirable retention
characteristics with this elution scheme. As shown in Figures 8 and 9, the compounds
exhibit sharp, well-defined peaks which appear after the void time indicated by the
small peaks which appear first on the chromatogram.68
Adjustments to the percentage of organic solvent were attempted following
the development of this scheme in an effort to improve the retention characteristics of
anabasine and nicotine; however, this was often accompanied by little to no retention
of the more acidic compounds myosmine and cotinine. Further adjustments to buffer
pH, buffer concentration, and organic solvent composition were similarly made as
further schemes were developed. The quantitative characteristics of these elution
schemes are given in Table 2; qualitative comments regarding these schemes are
given in Table 3.
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Anabasine

Nicotine

Myosmine

Cotinine

Anabasine

Nicotine

Myosmine

Cotinine

Table 2: Quantitative Data for Attempted Elution Schemes using Thermo Finnigan
HPLC
Mobile
Correlation Coefficient
λ
Phase
Retention Times (min)
2
(R ) Value
(nm)
No.*

1
2
3
4
5
6
7
8
9
10
11
12
13
14

260
260
3.392†
2.632 3.305‡ 4.384 5.502

0.3662†
0.9787 0.9956‡ 0.9971 0.9172

3.729 4.167
2.536 3.042 3.806 3.767
2.720 3.711 5.563 5.431 0.9999 0.9999
2.533 2.651
0.9854
2.54 3.505 8.802 13.631
2.263 2.233
2.042 2.07
0.9786 0.9892
2.072 2.085
7.218 3.662
2.955 2.356
2.843 4.6185 2.986 2.396
*The mobile phase number refers to those listed in Table 1.

260
& 234
260
260
260
260
260
260
260
260
260
260
260

†

These retention times refer to those obtained at a detection wavelength of 260 nm.

‡

These retention times refer to those obtained at a detection wavelength of 234 nm.
For mobile phases 1 and 2, the alkaloids could not be resolved from the
chromatogram.
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Table 3: Qualitative Data for Attempted Elution Schemes using Thermo Finnigan
HPLC
Mobile
Phase
Comments
No.*
1
No resolution
2
No resolution
Well-defined for cotinine and myosmine; broad nicotine and anabasine
3
peaks
4
significant tailing and split peaks for nicotine and anabasine
5
Tailing nicotine peak; broad anabasine peak
Well-defined for cotinine and myosmine; poor for nicotine and
6
anabasine
7
Well-defined peaks but poor retention
Well-defined for cotinine and myosmine; broad peaks for nicotine and
8
anabasine
9
Well-defined peaks but poor retention
10
Well-defined peaks but poor retention
11
Well-defined peaks but poor retention
12
Broad and poorly defined peaks
13
Well-defined with some tailing; poor retention
14
Split peaks for all analytes
*The mobile phase number refers to those listed in Table 1.
Upon purchasing the Agilent HPLC, gradient schemes could again be
developed in order to counter the general elution problem. A combination of the
previously attempted elution schemes with the best retention characteristics using the
Thermo Finnigan instrument led to those attempted on the Agilent instrument.
The initial scheme used 35% acetonitrile and 65 % 25 mM pH 7.9 phosphate
buffer run isocratically. Though peaks were narrow and well-defined for all alkaloids,
poor retention of cotinine and myosmine was observed—these compounds were
detected almost immediately after injection.
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To combat this problem and avoid an overlap with the column’s void time, the
organic solvent was switched from acetonitrile to methanol. This resulted in greater
retention without sacrificing the overall peak shape. Figure 12 demonstrates the
retention characteristics of myosmine and cotinine in 35% methanol and 65% 25 mM
pH 7.9 phosphate buffer. Calibration curves were constructed for all four alkaloids
using this isocratic method; these are given in Figures 13-16.

Figure 12: Chromatogram of Cotinine and Myosmine, 65/35 pH 7.9 Phosphate
Buffer/MeOH. Cotinine = 2.303 min., Myosmine = 4.157 min.
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Figure 13: Calibration Curve of Cotinine at 260 nm, 65/35 pH 7.9 Phosphate
Buffer/MeOH
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Figure 14: Calibration Curve of Anabasine at 260 nm, 65/35 pH 7.9 Phosphate
Buffer/MeOH
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Figure 15: Calibration Curve of Myosmine at 260 nm, 65/35 pH 7.9 Phosphate
Buffer/MeOH
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Figure 16: Calibration Curve of Nicotine at 260 nm, 65/35 pH 7.9 Phosphate
Buffer/MeOH

Upon finding desirable retention characteristics using this isocratic method,
mixed standards containing nicotine, anabasine, cotinine, and myosmine were

46

injected under same solvent conditions. The results are shown in Figure 17.
According to the figure, myosmine and cotinine again demonstrate excellent narrow
peaks with this method. Though anabasine and nicotine (eluted at 4.017 minutes and
5.811 minutes, respectively) exhibit broader peaks in comparison, the reproducibility
and overall peak shape was greatly improved when compared to results from the
Thermo Finnigan instrument. A significant overlap in retention between anabasine
and myosmine exists with this method, however—further adjustment was needed to
resolve these compounds.

Figure 17: Chromatogram of Alkaloids, 65/35 pH 7.9 Phosphate Buffer/MeOH
Cotinine = 2.334 min., Anabasine = 4.017 min., Myosmine = 4.263 min., Nicotine =
5.811 min. Note the co-elution of myosmine and anabasine.
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In order to resolve the peaks corresponding to anabasine and myosmine, the
percentage of methanol in the mobile phase was increased to 50%. An isocratic
method of 50% 25 mM pH 7.9 phosphate buffer and 50% methanol was used to elute
a mixed standard containing myosmine and anabasine. The results are shown in
Figure 18.

Figure 18: Chromatogram of Anabasine and Myosmine, 50/50 pH 7.9 Phosphate
Buffer/MeOH.
Myosmine = 2.252 min., Anabasine = 2.510 min. The top chromatogram used a
wavelength of detection of 260 nm; the bottom chromatogram used a wavelength of
detection of 234 nm.
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In order to gauge the efficacy of this method, the resolution between these
peaks was calculated. Chromatographic resolution may be calculated using Equation
4:

& 

'∆)
*+ ,*-

Eq. 4

where Rs is resolution, ∆Z is the difference in time between the peaks of interest, WA
is the width of the first eluted peak, and WB is the width of the second eluted peak.68
Since the widths W and the time difference Z are both given in units of time, Rs is a
unitless quantity. The average resolution measured between these peaks was
measured as 3.421 ± 0.022. A resolution greater than or equal to 1.5 is typically
deemed adequate for baseline separation between two peaks.70
Following these results, a gradient scheme was adapted by combining the two
above methods—the concentration of the organic solvent methanol was gradually
increased prior to the elution of the compounds myosmine, anabasine, and nicotine.
This resulted in a shift in retention order between anabasine and myosmine, causing
the more acidic alkaloid myosmine to elute before anabasine. Separation between
myosmine and anabasine was achieved, resulting in a simple gradient scheme only
6.5 minutes in length. This scheme is much shorter in comparison to the 30 minute
run time required to separate alkaloids in the FDA-funded study discussed
previously.6 The results of this method are demonstrated in Figure 19.
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Figure 19: Chromatogram of Alkaloids:
Cotinine = 1.685 min., Myosmine = 3.204 min., Anabasine = 3.706 min., Nicotine =
4.314 min. Alkaloids were analyzed using the following scheme: Gradient of 65/35
pH 7.9 Phosphate Buffer/MeOH to 50/50 pH 7.9 Phosphate Buffer/MeOH from 0 to
3 minutes; Isocratic 50/50 pH 7.9 Phosphate Buffer/MeOH from 3 to 6.5 min.

The overall peak shapes shown in Figure 15 suffered due to the presence of
contaminants on the chromatographic column. Repeated washings of the column with
HPLC-grade water and methanol led to a gradual improvement from split, broad
peaks to those shown above in Figure 19. Research was suspended in October of
2013 following maintenance on the chromatograph injection port and a need to clear
obstructions from the eluent lines and column.
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FUTURE WORK
The developed elution scheme may be improved by reducing the effects seen
from ionization of analytes due to a shift in pH. The addition of the mobile phase
buffer to the alkaloid samples prior to injection may enhance separation as well as
allow the alkaloids to equilibrate to the buffered portion of the mobile phase before
analysis. Existing literature demonstrates that low concentrations (approximately
0.1%) of strong acids such as trifluoroacetic acid may be added to the alkaloids prior
to injection to control the pH.83 This has limited efficacy for more basic analytes;
however, it has been used to control the mobile phase pH and selectivity for some
slightly ionizable compounds such as proteins. Care must be taken when pursuing this
option so as not to lower the mobile phase pH below the acceptable range for the
column (for the Agilent Poroshell column, this range is 2.0 – 9.0).80, 84
The original goal of this study was to test a variety of e-cigarette filling
solutions using a predetermined HPLC elution scheme found in the literature. During
the course of this work, instrument issues such as those discussed previously led to a
shift in focus from a quality control study regarding the alkaloid content in ecigarettes to a study in method development for e-cigarette alkaloids using mixed
standards. In the future, e-cigarette filling solutions will be diluted to 1/1000 of their
original concentrations and run using the HPLC elution scheme described in Figure
19. The concentrations of each alkaloid in the refill solutions will be reported along
with their statistical significance. Attention will be given to the concentration of
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nicotine found experimentally as it compares to the concentration advertised by the
manufacturer and amounts reported by pre-existing research.
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CONCLUSION
The goal of this work was to add to the growing amount of knowledge
regarding e-cigarette quality, safety, and efficacy by developing an HPLC elution
scheme capable of separating and quantifying nicotine and the related e-cigarette
alkaloids anabasine, cotinine, and myosmine. A simple gradient elution scheme was
developed with the following specifications: a transition from 65% to 50% 25 mM
pH 7.9 phosphate buffer was accompanied by an increase from 35% to 50% methanol
from 0 to 3 minutes, followed by isocratic elution from 3 to 6.5 minutes with 50% 25
mM pH 7.9 phosphate buffer and 50% methanol. This elution scheme was sufficient
to resolve all alkaloids with reasonable peak shape and separation. The method will
be used to quantify the amount of nicotine and related alkaloids in e-cigarette filling
solutions purchased from online vendors. The experimental nicotine concentrations
may then be compared to the manufacturers’ reported nicotine concentrations to
provide an assessment of the quality control surrounding e-cigarette filling solutions.
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